Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
>
Parkinson's Disease Treatment: Mirivadelgat Enters Phase 2a Study Trial
Parkinson's Disease Treatment: Mirivadelgat Enters Phase 2a Study Trial
Read also
AI in Drug Discovery: AdAlta Expands Biotech Pipeline With Octopi Network
AdAlta partners with Oktopi to integrate advanced artificial intelligence into its drug development workflows, optimizing investment and licensing decisions.
Cytomegalovirus Vaccine Development: Evaxion Unveils EVX-V1 Preclinical
Evaxion will present new preclinical data at IHW 2026 for EVX-V1, a novel AI-designed cytomegalovirus vaccine candidate addressing critical unmet needs.
Global Clinical Trials Network: Allucent Unveils IGNITE for Rapid Setup
Contract research organization Allucent launches the IGNITE network, connecting sponsors with over 250 pre-qualified sites to accelerate clinical trials.
New Obesity Treatment: iBio Antibody Spares Lean Mass Better Than GLP-1
Preclinical data shows iBio’s IBIO-610, a novel Activin E antibody, drives fat-selective weight loss and preserves lean mass when paired with GLP-1 drugs.
